UK’s GSK is blazing a trail in study yet AstraZeneca is not associated with the area, report finds
The pipe of new drugs to combat superbugs remains “worryingly slim” and has actually diminished by 35% in the last 5 years, experts have advised, predicting the yearly variety of deaths connected to drug-resistant infections globally will double to 8 million by 2050.
The variety of tasks from huge pharma firms has actually reduced by 35% over the previous 5 years, from 92 to 60 medications in development, according to a record from the Access to Medicine Foundation (AMF), a Netherlands-based charitable group, and the Wellcome Trust.
Source: The Guardian